Global Postmenopausal Vaginal Atrophy Drugs Market Growth 2024-2031

Report ID: 1331027 | Published Date: Jan 2025 | No. of Page: 105 | Base Year: 2024 | Rating: 3.7 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Scope of the Report
    1.1 Market Introduction
    1.2 Years Considered
    1.3 Research Objectives
    1.4 Market Research Methodology
    1.5 Research Process and Data Source
    1.6 Economic Indicators
    1.7 Currency Considered
2 Executive Summary
    2.1 World Market Overview
        2.1.1 Global Postmenopausal Vaginal Atrophy Drugs Annual Sales 2017-2028
        2.1.2 World Current & Future Analysis for Postmenopausal Vaginal Atrophy Drugs by Geographic Region, 2017, 2022 & 2028
        2.1.3 World Current & Future Analysis for Postmenopausal Vaginal Atrophy Drugs by Country/Region, 2017, 2022 & 2028
    2.2 Postmenopausal Vaginal Atrophy Drugs Segment by Type
        2.2.1 Vaginal Gels
        2.2.2 Creams
        2.2.3 Tablets
        2.2.4 Rings
        2.2.5 Patches
    2.3 Postmenopausal Vaginal Atrophy Drugs Sales by Type
        2.3.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2017-2022)
        2.3.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue and Market Share by Type (2017-2022)
        2.3.3 Global Postmenopausal Vaginal Atrophy Drugs Sale Price by Type (2017-2022)
    2.4 Postmenopausal Vaginal Atrophy Drugs Segment by Application
        2.4.1 Offline Stores
        2.4.2 Online Stores
    2.5 Postmenopausal Vaginal Atrophy Drugs Sales by Application
        2.5.1 Global Postmenopausal Vaginal Atrophy Drugs Sale Market Share by Application (2017-2022)
        2.5.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue and Market Share by Application (2017-2022)
        2.5.3 Global Postmenopausal Vaginal Atrophy Drugs Sale Price by Application (2017-2022)
3 Global Postmenopausal Vaginal Atrophy Drugs by Company
    3.1 Global Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Company
        3.1.1 Global Postmenopausal Vaginal Atrophy Drugs Annual Sales by Company (2020-2022)
        3.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company (2020-2022)
    3.2 Global Postmenopausal Vaginal Atrophy Drugs Annual Revenue by Company (2020-2022)
        3.2.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Company (2020-2022)
        3.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Company (2020-2022)
    3.3 Global Postmenopausal Vaginal Atrophy Drugs Sale Price by Company
    3.4 Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Producing Area Distribution, Sales Area, Product Type
        3.4.1 Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Location Distribution
        3.4.2 Players Postmenopausal Vaginal Atrophy Drugs Products Offered
    3.5 Market Concentration Rate Analysis
        3.5.1 Competition Landscape Analysis
        3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
    3.6 New Products and Potential Entrants
    3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Postmenopausal Vaginal Atrophy Drugs by Geographic Region
    4.1 World Historic Postmenopausal Vaginal Atrophy Drugs Market Size by Geographic Region (2017-2022)
        4.1.1 Global Postmenopausal Vaginal Atrophy Drugs Annual Sales by Geographic Region (2017-2022)
        4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Annual Revenue by Geographic Region
    4.2 World Historic Postmenopausal Vaginal Atrophy Drugs Market Size by Country/Region (2017-2022)
        4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Annual Sales by Country/Region (2017-2022)
        4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Annual Revenue by Country/Region
    4.3 Americas Postmenopausal Vaginal Atrophy Drugs Sales Growth
    4.4 APAC Postmenopausal Vaginal Atrophy Drugs Sales Growth
    4.5 Europe Postmenopausal Vaginal Atrophy Drugs Sales Growth
    4.6 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Growth
5 Americas
    5.1 Americas Postmenopausal Vaginal Atrophy Drugs Sales by Country
        5.1.1 Americas Postmenopausal Vaginal Atrophy Drugs Sales by Country (2017-2022)
        5.1.2 Americas Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2017-2022)
    5.2 Americas Postmenopausal Vaginal Atrophy Drugs Sales by Type
    5.3 Americas Postmenopausal Vaginal Atrophy Drugs Sales by Application
    5.4 United States
    5.5 Canada
    5.6 Mexico
    5.7 Brazil
6 APAC
    6.1 APAC Postmenopausal Vaginal Atrophy Drugs Sales by Region
        6.1.1 APAC Postmenopausal Vaginal Atrophy Drugs Sales by Region (2017-2022)
        6.1.2 APAC Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2017-2022)
    6.2 APAC Postmenopausal Vaginal Atrophy Drugs Sales by Type
    6.3 APAC Postmenopausal Vaginal Atrophy Drugs Sales by Application
    6.4 China
    6.5 Japan
    6.6 South Korea
    6.7 Southeast Asia
    6.8 India
    6.9 Australia
    6.10 China Taiwan
7 Europe
    7.1 Europe Postmenopausal Vaginal Atrophy Drugs by Country
        7.1.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2017-2022)
        7.1.2 Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2017-2022)
    7.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Type
    7.3 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Application
    7.4 Germany
    7.5 France
    7.6 UK
    7.7 Italy
    7.8 Russia
8 Middle East & Africa
    8.1 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs by Country
        8.1.1 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2017-2022)
        8.1.2 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2017-2022)
    8.2 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales by Type
    8.3 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales by Application
    8.4 Egypt
    8.5 South Africa
    8.6 Israel
    8.7 Turkey
    8.8 GCC Countries
9 Market Drivers, Challenges and Trends
    9.1 Market Drivers & Growth Opportunities
    9.2 Market Challenges & Risks
    9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
    10.1 Raw Material and Suppliers
    10.2 Manufacturing Cost Structure Analysis of Postmenopausal Vaginal Atrophy Drugs
    10.3 Manufacturing Process Analysis of Postmenopausal Vaginal Atrophy Drugs
    10.4 Industry Chain Structure of Postmenopausal Vaginal Atrophy Drugs
11 Marketing, Distributors and Customer
    11.1 Sales Channel
        11.1.1 Direct Channels
        11.1.2 Indirect Channels
    11.2 Postmenopausal Vaginal Atrophy Drugs Distributors
    11.3 Postmenopausal Vaginal Atrophy Drugs Customer
12 World Forecast Review for Postmenopausal Vaginal Atrophy Drugs by Geographic Region
    12.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Region
        12.1.1 Global Postmenopausal Vaginal Atrophy Drugs Forecast by Region (2023-2028)
        12.1.2 Global Postmenopausal Vaginal Atrophy Drugs Annual Revenue Forecast by Region (2023-2028)
    12.2 Americas Forecast by Country
    12.3 APAC Forecast by Region
    12.4 Europe Forecast by Country
    12.5 Middle East & Africa Forecast by Country
    12.6 Global Postmenopausal Vaginal Atrophy Drugs Forecast by Type
    12.7 Global Postmenopausal Vaginal Atrophy Drugs Forecast by Application
13 Key Players Analysis
    13.1 Actavis plc
        13.1.1 Actavis plc Company Information
        13.1.2 Actavis plc Postmenopausal Vaginal Atrophy Drugs Product Offered
        13.1.3 Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
        13.1.4 Actavis plc Main Business Overview
        13.1.5 Actavis plc Latest Developments
    13.2 Bionovo, Inc.
        13.2.1 Bionovo, Inc. Company Information
        13.2.2 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Product Offered
        13.2.3 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
        13.2.4 Bionovo, Inc. Main Business Overview
        13.2.5 Bionovo, Inc. Latest Developments
    13.3 Endoceutics, Inc.
        13.3.1 Endoceutics, Inc. Company Information
        13.3.2 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Product Offered
        13.3.3 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
        13.3.4 Endoceutics, Inc. Main Business Overview
        13.3.5 Endoceutics, Inc. Latest Developments
    13.4 Novo Nordisk A/S
        13.4.1 Novo Nordisk A/S Company Information
        13.4.2 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Product Offered
        13.4.3 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
        13.4.4 Novo Nordisk A/S Main Business Overview
        13.4.5 Novo Nordisk A/S Latest Developments
    13.5 Pfizer Inc.
        13.5.1 Pfizer Inc. Company Information
        13.5.2 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Product Offered
        13.5.3 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
        13.5.4 Pfizer Inc. Main Business Overview
        13.5.5 Pfizer Inc. Latest Developments
    13.6 Teva Pharmaceuticals Ltd.
        13.6.1 Teva Pharmaceuticals Ltd. Company Information
        13.6.2 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Product Offered
        13.6.3 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
        13.6.4 Teva Pharmaceuticals Ltd. Main Business Overview
        13.6.5 Teva Pharmaceuticals Ltd. Latest Developments
    13.7 Therapeutics MD, Inc.
        13.7.1 Therapeutics MD, Inc. Company Information
        13.7.2 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Product Offered
        13.7.3 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
        13.7.4 Therapeutics MD, Inc. Main Business Overview
        13.7.5 Therapeutics MD, Inc. Latest Developments
    13.8 Shionogi & Company
        13.8.1 Shionogi & Company Company Information
        13.8.2 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Product Offered
        13.8.3 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
        13.8.4 Shionogi & Company Main Business Overview
        13.8.5 Shionogi & Company Latest Developments
    13.9 Allergan plc
        13.9.1 Allergan plc Company Information
        13.9.2 Allergan plc Postmenopausal Vaginal Atrophy Drugs Product Offered
        13.9.3 Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
        13.9.4 Allergan plc Main Business Overview
        13.9.5 Allergan plc Latest Developments
    13.10 Shionogi & Co. Ltd.
        13.10.1 Shionogi & Co. Ltd. Company Information
        13.10.2 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Product Offered
        13.10.3 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
        13.10.4 Shionogi & Co. Ltd. Main Business Overview
        13.10.5 Shionogi & Co. Ltd. Latest Developments
14 Research Findings and Conclusion

List of Tables
    Table 1. Postmenopausal Vaginal Atrophy Drugs Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
    Table 2. Postmenopausal Vaginal Atrophy Drugs Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
    Table 3. Major Players of Vaginal Gels
    Table 4. Major Players of Creams
    Table 5. Major Players of Tablets
    Table 6. Major Players of Rings
    Table 7. Major Players of Patches
    Table 8. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2017-2022) & (K Units)
    Table 9. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2017-2022)
    Table 10. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2017-2022) & ($ million)
    Table 11. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2017-2022)
    Table 12. Global Postmenopausal Vaginal Atrophy Drugs Sale Price by Type (2017-2022) & (USD/Unit)
    Table 13. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2017-2022) & (K Units)
    Table 14. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2017-2022)
    Table 15. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2017-2022)
    Table 16. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2017-2022)
    Table 17. Global Postmenopausal Vaginal Atrophy Drugs Sale Price by Application (2017-2022) & (USD/Unit)
    Table 18. Global Postmenopausal Vaginal Atrophy Drugs Sales by Company (2020-2022) & (K Units)
    Table 19. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company (2020-2022)
    Table 20. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Company (2020-2022) ($ Millions)
    Table 21. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Company (2020-2022)
    Table 22. Global Postmenopausal Vaginal Atrophy Drugs Sale Price by Company (2020-2022) & (USD/Unit)
    Table 23. Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Producing Area Distribution and Sales Area
    Table 24. Players Postmenopausal Vaginal Atrophy Drugs Products Offered
    Table 25. Postmenopausal Vaginal Atrophy Drugs Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
    Table 26. New Products and Potential Entrants
    Table 27. Mergers & Acquisitions, Expansion
    Table 28. Global Postmenopausal Vaginal Atrophy Drugs Sales by Geographic Region (2017-2022) & (K Units)
    Table 29. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share Geographic Region (2017-2022)
    Table 30. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Geographic Region (2017-2022) & ($ millions)
    Table 31. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Geographic Region (2017-2022)
    Table 32. Global Postmenopausal Vaginal Atrophy Drugs Sales by Country/Region (2017-2022) & (K Units)
    Table 33. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country/Region (2017-2022)
    Table 34. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Country/Region (2017-2022) & ($ millions)
    Table 35. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country/Region (2017-2022)
    Table 36. Americas Postmenopausal Vaginal Atrophy Drugs Sales by Country (2017-2022) & (K Units)
    Table 37. Americas Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2017-2022)
    Table 38. Americas Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2017-2022) & ($ Millions)
    Table 39. Americas Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2017-2022)
    Table 40. Americas Postmenopausal Vaginal Atrophy Drugs Sales by Type (2017-2022) & (K Units)
    Table 41. Americas Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2017-2022)
    Table 42. Americas Postmenopausal Vaginal Atrophy Drugs Sales by Application (2017-2022) & (K Units)
    Table 43. Americas Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2017-2022)
    Table 44. APAC Postmenopausal Vaginal Atrophy Drugs Sales by Region (2017-2022) & (K Units)
    Table 45. APAC Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2017-2022)
    Table 46. APAC Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2017-2022) & ($ Millions)
    Table 47. APAC Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2017-2022)
    Table 48. APAC Postmenopausal Vaginal Atrophy Drugs Sales by Type (2017-2022) & (K Units)
    Table 49. APAC Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2017-2022)
    Table 50. APAC Postmenopausal Vaginal Atrophy Drugs Sales by Application (2017-2022) & (K Units)
    Table 51. APAC Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2017-2022)
    Table 52. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2017-2022) & (K Units)
    Table 53. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2017-2022)
    Table 54. Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2017-2022) & ($ Millions)
    Table 55. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2017-2022)
    Table 56. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Type (2017-2022) & (K Units)
    Table 57. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2017-2022)
    Table 58. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Application (2017-2022) & (K Units)
    Table 59. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2017-2022)
    Table 60. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2017-2022) & (K Units)
    Table 61. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2017-2022)
    Table 62. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2017-2022) & ($ Millions)
    Table 63. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2017-2022)
    Table 64. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales by Type (2017-2022) & (K Units)
    Table 65. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2017-2022)
    Table 66. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales by Application (2017-2022) & (K Units)
    Table 67. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2017-2022)
    Table 68. Key Market Drivers & Growth Opportunities of Postmenopausal Vaginal Atrophy Drugs
    Table 69. Key Market Challenges & Risks of Postmenopausal Vaginal Atrophy Drugs
    Table 70. Key Industry Trends of Postmenopausal Vaginal Atrophy Drugs
    Table 71. Postmenopausal Vaginal Atrophy Drugs Raw Material
    Table 72. Key Suppliers of Raw Materials
    Table 73. Postmenopausal Vaginal Atrophy Drugs Distributors List
    Table 74. Postmenopausal Vaginal Atrophy Drugs Customer List
    Table 75. Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Region (2023-2028) & (K Units)
    Table 76. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Forecast by Region
    Table 77. Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
    Table 78. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share Forecast by Region (2023-2028)
    Table 79. Americas Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2023-2028) & (K Units)
    Table 80. Americas Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
    Table 81. APAC Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Region (2023-2028) & (K Units)
    Table 82. APAC Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
    Table 83. Europe Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2023-2028) & (K Units)
    Table 84. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
    Table 85. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2023-2028) & (K Units)
    Table 86. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
    Table 87. Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Type (2023-2028) & (K Units)
    Table 88. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share Forecast by Type (2023-2028)
    Table 89. Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Type (2023-2028) & ($ Millions)
    Table 90. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share Forecast by Type (2023-2028)
    Table 91. Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Application (2023-2028) & (K Units)
    Table 92. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share Forecast by Application (2023-2028)
    Table 93. Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Application (2023-2028) & ($ Millions)
    Table 94. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share Forecast by Application (2023-2028)
    Table 95. Actavis plc Basic Information, Postmenopausal Vaginal Atrophy Drugs Manufacturing Base, Sales Area and Its Competitors
    Table 96. Actavis plc Postmenopausal Vaginal Atrophy Drugs Product Offered
    Table 97. Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 98. Actavis plc Main Business
    Table 99. Actavis plc Latest Developments
    Table 100. Bionovo, Inc. Basic Information, Postmenopausal Vaginal Atrophy Drugs Manufacturing Base, Sales Area and Its Competitors
    Table 101. Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Product Offered
    Table 102. Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 103. Bionovo, Inc. Main Business
    Table 104. Bionovo, Inc. Latest Developments
    Table 105. Endoceutics, Inc. Basic Information, Postmenopausal Vaginal Atrophy Drugs Manufacturing Base, Sales Area and Its Competitors
    Table 106. Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Product Offered
    Table 107. Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 108. Endoceutics, Inc. Main Business
    Table 109. Endoceutics, Inc. Latest Developments
    Table 110. Novo Nordisk A/S Basic Information, Postmenopausal Vaginal Atrophy Drugs Manufacturing Base, Sales Area and Its Competitors
    Table 111. Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Product Offered
    Table 112. Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 113. Novo Nordisk A/S Main Business
    Table 114. Novo Nordisk A/S Latest Developments
    Table 115. Pfizer Inc. Basic Information, Postmenopausal Vaginal Atrophy Drugs Manufacturing Base, Sales Area and Its Competitors
    Table 116. Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Product Offered
    Table 117. Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 118. Pfizer Inc. Main Business
    Table 119. Pfizer Inc. Latest Developments
    Table 120. Teva Pharmaceuticals Ltd. Basic Information, Postmenopausal Vaginal Atrophy Drugs Manufacturing Base, Sales Area and Its Competitors
    Table 121. Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Product Offered
    Table 122. Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 123. Teva Pharmaceuticals Ltd. Main Business
    Table 124. Teva Pharmaceuticals Ltd. Latest Developments
    Table 125. Therapeutics MD, Inc. Basic Information, Postmenopausal Vaginal Atrophy Drugs Manufacturing Base, Sales Area and Its Competitors
    Table 126. Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Product Offered
    Table 127. Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 128. Therapeutics MD, Inc. Main Business
    Table 129. Therapeutics MD, Inc. Latest Developments
    Table 130. Shionogi & Company Basic Information, Postmenopausal Vaginal Atrophy Drugs Manufacturing Base, Sales Area and Its Competitors
    Table 131. Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Product Offered
    Table 132. Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 133. Shionogi & Company Main Business
    Table 134. Shionogi & Company Latest Developments
    Table 135. Allergan plc Basic Information, Postmenopausal Vaginal Atrophy Drugs Manufacturing Base, Sales Area and Its Competitors
    Table 136. Allergan plc Postmenopausal Vaginal Atrophy Drugs Product Offered
    Table 137. Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 138. Allergan plc Main Business
    Table 139. Allergan plc Latest Developments
    Table 140. Shionogi & Co. Ltd. Basic Information, Postmenopausal Vaginal Atrophy Drugs Manufacturing Base, Sales Area and Its Competitors
    Table 141. Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Product Offered
    Table 142. Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 143. Shionogi & Co. Ltd. Main Business
    Table 144. Shionogi & Co. Ltd. Latest Developments
List of Figures
    Figure 1. Picture of Postmenopausal Vaginal Atrophy Drugs
    Figure 2. Postmenopausal Vaginal Atrophy Drugs Report Years Considered
    Figure 3. Research Objectives
    Figure 4. Research Methodology
    Figure 5. Research Process and Data Source
    Figure 6. Global Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2017-2028 (K Units)
    Figure 7. Global Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2017-2028 ($ Millions)
    Figure 8. Postmenopausal Vaginal Atrophy Drugs Sales by Region (2021 & 2028) & ($ millions)
    Figure 9. Product Picture of Vaginal Gels
    Figure 10. Product Picture of Creams
    Figure 11. Product Picture of Tablets
    Figure 12. Product Picture of Rings
    Figure 13. Product Picture of Patches
    Figure 14. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2021
    Figure 15. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2017-2022)
    Figure 16. Postmenopausal Vaginal Atrophy Drugs Consumed in Offline Stores
    Figure 17. Global Postmenopausal Vaginal Atrophy Drugs Market: Offline Stores (2017-2022) & (K Units)
    Figure 18. Postmenopausal Vaginal Atrophy Drugs Consumed in Online Stores
    Figure 19. Global Postmenopausal Vaginal Atrophy Drugs Market: Online Stores (2017-2022) & (K Units)
    Figure 20. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2017-2022)
    Figure 21. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application in 2021
    Figure 22. Postmenopausal Vaginal Atrophy Drugs Revenue Market by Company in 2021 ($ Million)
    Figure 23. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Company in 2021
    Figure 24. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Geographic Region (2017-2022)
    Figure 25. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Geographic Region in 2021
    Figure 26. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2017-2022)
    Figure 27. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country/Region in 2021
    Figure 28. Americas Postmenopausal Vaginal Atrophy Drugs Sales 2017-2022 (K Units)
    Figure 29. Americas Postmenopausal Vaginal Atrophy Drugs Revenue 2017-2022 ($ Millions)
    Figure 30. APAC Postmenopausal Vaginal Atrophy Drugs Sales 2017-2022 (K Units)
    Figure 31. APAC Postmenopausal Vaginal Atrophy Drugs Revenue 2017-2022 ($ Millions)
    Figure 32. Europe Postmenopausal Vaginal Atrophy Drugs Sales 2017-2022 (K Units)
    Figure 33. Europe Postmenopausal Vaginal Atrophy Drugs Revenue 2017-2022 ($ Millions)
    Figure 34. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales 2017-2022 (K Units)
    Figure 35. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue 2017-2022 ($ Millions)
    Figure 36. Americas Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country in 2021
    Figure 37. Americas Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country in 2021
    Figure 38. United States Postmenopausal Vaginal Atrophy Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 39. Canada Postmenopausal Vaginal Atrophy Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 40. Mexico Postmenopausal Vaginal Atrophy Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 41. Brazil Postmenopausal Vaginal Atrophy Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 42. APAC Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region in 2021
    Figure 43. APAC Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Regions in 2021
    Figure 44. China Postmenopausal Vaginal Atrophy Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 45. Japan Postmenopausal Vaginal Atrophy Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 46. South Korea Postmenopausal Vaginal Atrophy Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 47. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 48. India Postmenopausal Vaginal Atrophy Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 49. Australia Postmenopausal Vaginal Atrophy Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 50. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country in 2021
    Figure 51. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country in 2021
    Figure 52. Germany Postmenopausal Vaginal Atrophy Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 53. France Postmenopausal Vaginal Atrophy Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 54. UK Postmenopausal Vaginal Atrophy Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 55. Italy Postmenopausal Vaginal Atrophy Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 56. Russia Postmenopausal Vaginal Atrophy Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 57. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country in 2021
    Figure 58. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country in 2021
    Figure 59. Egypt Postmenopausal Vaginal Atrophy Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 60. South Africa Postmenopausal Vaginal Atrophy Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 61. Israel Postmenopausal Vaginal Atrophy Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 62. Turkey Postmenopausal Vaginal Atrophy Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 63. GCC Country Postmenopausal Vaginal Atrophy Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 64. Manufacturing Cost Structure Analysis of Postmenopausal Vaginal Atrophy Drugs in 2021
    Figure 65. Manufacturing Process Analysis of Postmenopausal Vaginal Atrophy Drugs
    Figure 66. Industry Chain Structure of Postmenopausal Vaginal Atrophy Drugs
    Figure 67. Channels of Distribution
    Figure 68. Distributors Profiles
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Please ask for Sample Report to see list of companies covered. Request Sample Report
Frequently Asked Questions
Global Postmenopausal Vaginal Atrophy Drugs Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Global Postmenopausal Vaginal Atrophy Drugs Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Global Postmenopausal Vaginal Atrophy Drugs Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports